Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Elizabeth K. O'Donnell"'
Autor:
Clifton C. Mo, Andrew J. Yee, Shonali Midha, Monique A. Hartley‐Brown, Omar Nadeem, Elizabeth K. O'Donnell, Giada Bianchi, Adam S. Sperling, Jacob P. Laubach, Paul G. Richardson
Publikováno v:
eJHaem, Vol 4, Iss 3, Pp 792-810 (2023)
Abstract Selinexor is an orally bioavailable selective inhibitor of nuclear export compound that inhibits exportin‐1 (XPO1), a novel therapeutic target that is overexpressed in multiple myeloma (MM) and is responsible for the transport of ∼220 nu
Externí odkaz:
https://doaj.org/article/df6d5d22d8aa4c3088dccaac48019fd0
Autor:
Kevin Charles Miller, Patrick Connor Johnson, Jeremy S. Abramson, Jacob D. Soumerai, Andrew J. Yee, Andrew R. Branagan, Elizabeth K. O’Donnell, Anna Saucier, Caron A. Jacobson, Matthew J. Frigault, Noopur S. Raje
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 10, Pp 1-12 (2022)
Abstract Chimeric antigen receptor T cells (CAR T) are groundbreaking therapies but may cause significant toxicities including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and cytopenias. Granulocyt
Externí odkaz:
https://doaj.org/article/3228817cf75c47368f94792a61f6aa4d
Autor:
Pouneh K. Fazeli, Miriam A. Bredella, Gisela Pachon-Peña, Wenxiu Zhao, Xun Zhang, Alexander T. Faje, Megi Resulaj, Sai P. Polineni, Tara M. Holmes, Hang Lee, Elizabeth K. O’Donnell, Ormond A. MacDougald, Mark C. Horowitz, Clifford J. Rosen, Anne Klibanski
Publikováno v:
JCI Insight, Vol 6, Iss 12 (2021)
BACKGROUND Adipocytes were long considered inert components of the bone marrow niche, but mouse and human models suggest bone marrow adipose tissue (BMAT) is dynamic and responsive to hormonal and nutrient cues.METHODS In this study of healthy volunt
Externí odkaz:
https://doaj.org/article/f9b9b856c1e14301bb81e9b24e87630a
Autor:
Matthew J. Frigault, Michael R. Bishop, Jacalyn Rosenblatt, Elizabeth K. O’Donnell, Noopur Raje, Daniella Cook, Andrew J. Yee, Emma Logan, David E. Avigan, Andrzej Jakubowiak, Kit Shaw, Heather Daley, Sarah Nikiforow, Faith Griffin, Christine Cornwell, Angela Shen, Christopher Heery, Marcela V. Maus
Publikováno v:
Blood Advances. 7:768-777
Relapsed and refractory multiple myeloma (RRMM) is a plasma cell neoplasm defined by progressively refractory disease necessitating chronic and increasingly intensive therapy. Despite recent advances, limited treatment options exist for RRMM. This si
Autor:
Elizabeth K. O’Donnell, Yael N. Shapiro, Andrew J. Yee, Omar Nadeem, Jacob P. Laubach, Andrew R. Branagan, Kenneth C. Anderson, Clifton C. Mo, Nikhil C. Munshi, Irene M. Ghobrial, Adam S. Sperling, Emerentia A. Agyemang, Jill N. Burke, Cynthia C. Harrington, Bonnie Y. Hu, Paul G. Richardson, Noopur S. Raje, Areej El-Jawahri
Publikováno v:
Blood Advances. 6:4967-4974
Although caregivers of patients with multiple myeloma (MM) play a critical role in supporting their loved ones throughout the illness course, studies examining caregiver quality of life (QOL), psychological distress, and prognostic awareness are lack
Autor:
Andrew R. Branagan, Matthew M Lei, Clifton C Mo, Andrew J. Yee, Elizabeth K. O'Donnell, Jorge J. Castillo, Omar Nadeem, Noopur Raje, Steven P Treon, Paul G. Richardson, Rie Nakamoto-Matsubara, Kirsten Meid, Zachary S. Bernstein, Rebecca T. Lyons, Rakesh Verma, Zachary R Hunter, Maria Luisa Guerrera, Catherine A. Flynn, Jill N. Burke, Cynthia C. Harrington, Emerentia Agyemang, Marilyn T. Gammon, Kathleen J. Lively, Lisette Packer, Nora K. Horick, Shayna Sarosiek
Publikováno v:
Blood. 140:10094-10096
Autor:
Elizabeth K. O'Donnell, Yael N. Shapiro, Amy Comander, Steven J. Isakoff, Beverly Moy, Laura Spring, Seth Wander, Irene Kuter, Jennifer Shin, Jerry Younger, Michelle Specht, Chryssanthi Kourniotis, Carol Sullivan, Loren Winters, Nora Horick, Jeffrey Peppercorn
Publikováno v:
Cancer Research. 82:PD5-11
Background: Prior, retrospective analysis of nightly fasting among women with breast cancer suggests that fasting less than 13 hours per night may be associated with higher risk of breast cancer recurrence. Small studies suggest that fasting duration
Autor:
Elizabeth K. O’Donnell, Yael N. Shapiro, Andrew J. Yee, Omar Nadeem, Bonnie Y. Hu, Jacob P. Laubach, Andrew R. Branagan, Kenneth C. Anderson, Clifton C. Mo, Nikhil C. Munshi, Irene M. Ghobrial, Adam S. Sperling, Emerentia A. Agyemang, Jill N. Burke, Cynthia C. Harrington, Paul G. Richardson, Noopur S. Raje, Areej El‐Jawahri
Publikováno v:
Cancer. 128:1996-2004
Multiple myeloma (MM) is an incurable hematologic malignancy requiring long-term, continuous therapy. Despite its chronic and unrelenting course, studies examining quality of life (QOL), psychological distress, and perceptions of prognosis by line of
Autor:
Kenneth C. Anderson, Daniel Auclair, Stacey J. Adam, Amit Agarwal, Melissa Anderson, Hervé Avet-Loiseau, Mark Bustoros, Jessica Chapman, Dana E. Connors, Ajeeta Dash, Alessandra Di Bacco, Ling Du, Thierry Facon, Juan Flores-Montero, Francesca Gay, Irene M. Ghobrial, Nicole J. Gormley, Ira Gupta, Howard Higley, Jens Hillengass, Bindu Kanapuru, Dickran Kazandjian, Gary J. Kelloff, Ilan R. Kirsch, Brandon Kremer, Ola Landgren, Elizabeth Lightbody, Oliver C. Lomas, Sagar Lonial, María-Victoria Mateos, Rocio Montes de Oca, Lata Mukundan, Nikhil C. Munshi, Elizabeth K. O'Donnell, Alberto Orfao, Bruno Paiva, Reshma Patel, Trevor J. Pugh, Karthik Ramasamy, Jill Ray, Mikhail Roshal, Jeremy A. Ross, Caroline C. Sigman, Katie L. Thoren, Suzanne Trudel, Gary Ulaner, Nancy Valente, Brendan M. Weiss, Elena Zamagni, Shaji K. Kumar
Publikováno v:
Clinical Cancer Research. 27:5195-5212
The development of novel agents has transformed the treatment paradigm for multiple myeloma, with minimal residual disease (MRD) negativity now achievable across the entire disease spectrum. Bone marrow–based technologies to assess MRD, including a
Autor:
Christopher Tyson, Elizabeth K. O'Donnell, Elliot Fishman, Vijay Parthasarathy, Tomasz M. Beer
Publikováno v:
Cancer Research. 83:769-769
Introduction: Blood-based multi-cancer early detection (MCED) tests in development may substantially expand the number of “screenable” cancers. Defining an optimal approach for tissue of origin (TOO) localization in individuals with cancer-suspec